TOGETHER

Vyxeos® Liposomal is the first dual-drug advanced liposomal formulation of daunorubicin and cytarabine1

LONGER

Vyxeos® Liposomal is the first chemotherapy to significantly increase overall median survival vs conventional chemotherapy* in patients with high-risk** AML2

TOGETHER

Vyxeos® Liposomal is the first dual-drug advanced liposomal formulation of daunorubicin and cytarabine1

LONGER

Vyxeos® Liposomal is the first chemotherapy to significantly increase overall median survival vs conventional chemotherapy* in patients with high-risk** AML2

Utilising advanced dual-drug liposomal technology to optimise the delivery of daunorubicin and cytarabine to significantly improve efficacy1,2

https://vyxeos.eu/wp-content/uploads/2018/08/Moa_16x9_screenshot.png

Mechanism of Action

NEW 5-YEAR FOLLOW-UP DATA

Vyxeos Liposomal significantly increases overall median survival compared with conventional chemotherapy* in patients with high-risk** AML2

https://vyxeos.eu/wp-content/uploads/2020/06/thumbnail-371px-1.jpg

Phase 3 Study & Follow-up data

Vyxeos Liposomal offers a 90-minute infusion schedule3

https://vyxeos.eu/wp-content/uploads/2020/01/VXYEOS_GRAPH_ADMINISTRATION.jpg

Preparation & Dosing

Vyxeos Liposomal is indicated for the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)3

*comparator arm conventional chemotherapy is 7+3 in induction, 5+2 in second induction and consolidation where given
**High-risk AML is defined as therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

References

  1. Tolcher AW, Mayer LD. Future Oncol 2018; 14(13): 1317-1332
  2. Lancet JE et al. J Clin Oncol 2018; 36(26): 2684-2692
  3. Vyxeos Liposomal – Summary of Product Characteristics, October 2019

 

ADVERSE EVENTS REPORTING

 

Reporting of side effects: Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse reactions via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email: AEreporting@jazzpharma.com or by fax to +44 (0) 1865 598765

 

INT-VYX-2000063 | June 2020